| Identification | Back Directory | [Name]
VUF 11207 fumarate | [CAS]
1785665-61-3 | [Synonyms]
VUF 11207 fumarate
N-[(2E)-3-(2-Fluorophenyl)-2-methyl-2-propen-1-yl]-3,4,5-trimethoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]benzamide fumarate | [Molecular Formula]
C31H39FN2O8 | [MDL Number]
MFCD27991278 | [MOL File]
1785665-61-3.mol | [Molecular Weight]
586.648 |
| Hazard Information | Back Directory | [Uses]
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation[1]. | [in vivo]
VUF11207 fumarate (100 μg/day; s.c.; single daily for 5 days) inhibits LPS?induced osteoclastogenesis, bone resorption and production of RANKL and TNF?α in mice[1]. | Animal Model: | Male c57Bl/6J wild?type/WT mice (8?10?week?old; 20?25 g; LPS-induced)[1] | | Dosage: | 100 μg/day | | Administration: | Subcutaneous injection; single daily for 5 days | | Result: | Significantly decreased the number of osteoclasts and suppressed Cathepsin K mRNA, ranKl and TnF?α mRNA expression levels.
Reduced the area of LPS-induced bone resorption.
|
| [IC 50]
CXCR7: 8.1 (pKi) | [storage]
Store at -20°C | [References]
[1] Wijtmans M, et al. Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem. 2012 May;51:184-92. DOI:10.1016/j.ejmech.2012.02.041
[2] Nugraha AP, et al. C?X?C receptor 7 agonist acts as a C?X?C motif chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone resorption. Mol Med Rep. 2022 Mar;25(3):78. DOI:10.3892/mmr.2022.12594 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
| Company Name: |
hangzhoubaiyibiolog
|
| Tel: |
15658107580 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList1389215/0_EN.htm |
|